profit from every ₹100 of sales.
₹0₹100
Ipca Laboratories
₹1,959.70+1.08% today
+37.5% in 1 year
1-year low ₹1,386.201-year high ₹2,009.60
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹43.57 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ipca Laboratories sold, what it kept, and what it did with the cash.
Sales went from ₹62.1 billion in 2023 to ₹96.5 billion in 2026, with ₹11.4 billion of profit last year.
SalesProfit
Ipca Laboratories handed back 11% of the cash it generated last year.
₹524M
Free cash flow 2026₹4.9B
Bought back its own shares–
Paid as dividends₹524M
Cash vs. debt₹4.4B vs. ₹8.1B
Ipca Laboratories vs. similar companies
Ipca Laboratories grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Ipca Laboratories | 43.6× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Ipca Laboratories's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 62,069 | 76,224 | 89,396 | 96,463 | |
| 37,993 | 48,966 | 61,610 | 68,236 | |
| 7,048 | 9,345 | 13,283 | 15,604 | |
| 10,519 | 13,372 | 16,139 | 20,666 | |
| 4,713 | 5,474 | 7,377 | 11,411 | |
| 18.58 | 21.57 | 29.08 | – | |
| 61.2% | 64.2% | 68.9% | 70.7% | |
| 11.4% | 12.3% | 14.9% | 16.2% | |
| 7.6% | 7.2% | 8.3% | 11.8% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 86,264 | 111,013 | 117,606 | 123,702 |
| Cash | 12,579 | 2,089 | 1,672 | 4,371 |
| Total debt | 14,813 | 14,384 | 13,627 | 8,088 |
| Total liabilities | 27,111 | 33,743 | 33,723 | 28,461 |
| 58,420 | 63,322 | 69,485 | 80,638 | |
| 254 | 254 | 254 | – | |
| 8.1% | 9.5% | 11.0% | 13.9% | |
| 8.1% | 8.6% | 10.6% | 14.2% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 8,058 | 9,447 | 13,213 | 11,420 | |
| 4,945 | 4,113 | 7,756 | 6,560 | |
| 3,113 | 5,334 | 5,458 | 4,860 | |
| Dividends paid | 1,015 | 507 | 1,015 | 524 |
| – | – | – | – | |
| 0 | 31 | 21 | 8 |
Valuation
- 43.6×
- –
- –
- 5.1×
- 5.2×
- 102.3×
- 24.2×
- 1.0%
- 2.3%
- 0.1%
Profitability
- 70.7%
- 16.2%
- 11.8%
- –
- 13.9%
- 10.6%
- –
- –
- –
- –
Growth
- +15.8%
- –
- –
- –
- −0.0%
Financial health
- 0.2×
- 0.10
- –
- 21.7×
- 2.76
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 16%of 948
Top 32%of 871
Bottom 29%of 560
Top 36%of 868
Bottom 48%of 985
0.1%of the share price, paid each year
On $1,000 invested$1a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
4.6% of its profit
Room to growStretchedMore than it earns: 10.8%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
44No pass
Philip Fisher
51No pass
Peter Lynch
74Pass
Joel Greenblatt
11No pass
Charlie Munger
44No pass
Terry Smith
36No pass
Questions about Ipca Laboratories
Is Ipca Laboratories a good stock to buy?
A solid business, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ipca Laboratories AI analysis
What does Ipca Laboratories do?
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. It is in Drug Manufacturers - Specialty & Generic, based in Mumbai, India.
Does Ipca Laboratories pay a dividend?
Yes. At today's price the dividend is 0.1% a year, about 5% of its yearly profit. In 2026 it paid out ₹524 million in dividends.
Is Ipca Laboratories stock halal?
Yes. Ipca Laboratories passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Ipca Laboratories stock done over the past year?
Up 37.5% over the past twelve months, to ₹1,959.70. It traded between ₹1,386.20 and ₹2,009.60 and is 2.5% below its high.
Who are Ipca Laboratories's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Ipca Laboratories's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.